NASDAQ:CCCC C4 Therapeutics Q3 2026 Earnings Date & Estimates $3.16 +0.31 (+10.88%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$3.15 -0.01 (-0.25%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. C4 Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 4, 2026 at 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 4, 2026Conference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from C4 Therapeutics in Q3 2026C4 Therapeutics is expected to post earnings of -$0.2010 per share on revenue of $8.85 million. In the same quarter a year earlier C4 Therapeutics reported -$0.44 per share on revenue of $11.23 million. C4 Therapeutics last reported on August 11, 2026, posting -$0.18 per share and beating the -$0.2264 consensus estimate. C4 Therapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.2010Expected Revenue$8.85 millionPrior-Year EPS-$0.44Prior-Year Revenue$11.23 millionExpected Revenue Growth-21.2%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.18 (Beat by +$0.0464)Last Quarter Revenue$6.64 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report C4 Therapeutics Q3 2026 Earnings FAQ When does C4 Therapeutics report Q3 2026 earnings? C4 Therapeutics (NASDAQ:CCCC) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is C4 Therapeutics' Q3 2026 earnings call? C4 Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for C4 Therapeutics? Analysts expect C4 Therapeutics to post earnings of -$0.2010 per share for Q3 2026. How much revenue is C4 Therapeutics expected to report? The consensus revenue estimate for C4 Therapeutics is $8.85 million for Q3 2026. C4 Therapeutics Earnings HeadlinesCoya Therapeutics (NASDAQ:COYA) and C4 Therapeutics (NASDAQ:CCCC) Financial ReviewOctober 6, 2026 | americanbankingnews.comComparing Immatics (NASDAQ:IMTX) & C4 Therapeutics (NASDAQ:CCCC)October 3, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 10 at 1:00 AM | Weiss Ratings (Ad)Cemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma StudySeptember 26, 2026 | rttnews.comC4 Therapeutics, Inc. Presents New Biomarker Data from Cemsidomide Phase 1 Trial With Dexamethasone and Phase 1b Trial With Elranatamab in Relapsed/Refractory Multiple MyelomaSeptember 25, 2026 | marketscreener.comMC4 Therapeutics presenta i dati sui biomarcatori del trial di cemsidomideSeptember 25, 2026 | it.investing.comSee More C4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email. Email Address About C4 TherapeuticsC4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to direct the body’s natural cellular machinery to identify and remove specific proteins that contribute to cancer and other diseases. C4 Therapeutics’ proprietary TORPEDO platform is used to discover and develop small-molecule protein degraders. Its research and development programs have included therapies aimed at targets implicated in blood cancers, solid tumors and genetically defined cancers, including programs directed at IKZF1/3, BRD9 and mutant BRAF. The company has also pursued collaborations intended to apply targeted protein degradation to additional therapeutic areas. Founded in 2015, C4 Therapeutics is headquartered in Watertown, Massachusetts. The company conducts its research primarily in the United States and has worked with international pharmaceutical partners to advance selected discovery and development programs. Andrew J. Hirsch serves as president and chief executive officer.View C4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
